MORE►
omaveloxolone
In a pivotal year, which saw Reata Pharmaceuticals halt research for a kidney disease treatment and receive FDA approval for its first-to-market degenerative disease treatment, the company welcomes Dr. Rajiv Patni as Chief R&D Officer. Patni marks this as an "inflection point to become a global, commercial-stage company with an expanding pipeline in both rare and common serious diseases."
Plano’s Reata Pharmaceuticals Appoints EVP/Chief R&D Officer
by Lance Murray | Jun 16, 2023
In a pivotal year, which saw Reata Pharmaceuticals halt research for a kidney disease treatment and receive FDA approval for its first-to-market degenerative disease treatment, the company welcomes Dr. Rajiv Patni as Chief R&D Officer. Patni marks this as an "inflection point to become a global, commercial-stage company with an expanding pipeline in both rare and common serious diseases."
